Pravastatin Therapy and the Risk of Stroke
暂无分享,去创建一个
David Colquhoun | Paul Glasziou | Stephen MacMahon | Andrew Tonkin | Graeme J. Hankey | Harvey D. White | R. J. Simes | Neil E. Anderson | John D.G. Watson | David M. Hunt | Adrienne Kirby | Malcolm J. West
[1] Elisa T. Lee,et al. Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.
[2] Z. Li,et al. Blood pressure, cholesterol, and stroke in eastern Asia , 1998, The Lancet.
[3] R. Westendorp,et al. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.
[4] J. Norris,et al. Outcome in patients with asymptomatic neck bruits. , 1986, The New England journal of medicine.
[5] D. Cox. Regression Models and Life-Tables , 1972 .
[6] C. Furberg,et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.
[7] A. Tonkin,et al. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. , 1995, Stroke.
[8] C. Furberg,et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.
[9] R. Virmani,et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. , 1996, Journal of vascular surgery.
[10] A. Sharrett,et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[11] H. White,et al. Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy , 1998 .
[12] W. Mack,et al. Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.
[13] B. Davis,et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. , 1999, Circulation.
[14] J. Holmes,et al. Lifetime cost of stroke in the United States. , 1996, Stroke.
[15] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[16] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[17] P. Libby,et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.
[18] R. D'Agostino,et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study , 1994, Neurology.
[19] J. Kjekshus,et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). , 1998, The American journal of cardiology.
[20] S. Azen,et al. Reduction in Carotid Arterial Wall Thickness Using Lovastatin and Dietary Therapy , 1996, Annals of Internal Medicine.
[21] A. Yeung,et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.
[22] G. Gallus,et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.
[23] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[24] J. Slattery,et al. Prognosis and prognostic factors of retinal infarction: a prospective cohort study. , 1991, BMJ.
[25] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[26] Alan D. Lopez,et al. Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.
[27] W. Liboni,et al. Effect of Lipid-Lowering Treatment on Progression of Atherosclerotic Lesions—a Duplex Ultrasonographic Investigation , 1995, Angiology.
[28] J. Crouse,et al. Assessment and management of carotid disease. , 1992, Annual review of medicine.
[29] C. Hennekens,et al. An overview of trials of cholesterol lowering and risk of stroke. , 1995, Archives of internal medicine.
[30] D. Kromhout. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.
[31] P A Wolf,et al. American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke: executive summary. , 1997, Circulation.
[32] G. Guyatt,et al. Effect of HMGcoA Reductase Inhibitors on Stroke , 1998, Annals of Internal Medicine.
[33] W. Weintraub,et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.
[34] D. Jacobs,et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.
[35] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[36] D. Waters,et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.
[37] J. Salonen,et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.
[38] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.